Canurta Signs LOI with extractX, Advances CNR-401, and Hits AI Milestone

Strategic Growth Update: Canurta Signs LOI to Merge with extractX

Canurta Therapeutics has signed a Letter of Intent (LOI) to merge with extractX Ltd., a global leader in mobile GMP-grade botanical extraction. This proposed amalgamation would combine Canurta’s drug development platform and intellectual property with extractX’s operational infrastructure, revenue-generating mobile labs, and international footprint.

The merger positions the combined company for a listing on the Canadian Securities Exchange (CSE) between late 2025 and early 2026, expanding our capital access and global reach. Together, we aim to accelerate the production of proprietary polyphenol-based therapeutics, integrate scalable infrastructure, and unlock new IP licensing opportunities across extractX’s partner network.

Due diligence is underway, and further updates will be provided as we progress toward a definitive agreement and public listing.

Read More

CNR-401 Progresses to Next Phase of Preclinical Development

Preliminary dose-ranging studies in mice have been successfully completed, establishing a safe dosing profile for CNR-401. With this milestone achieved, we are now initiating the next phase, evaluating the ability of CNR-401’s active compounds to cross the blood-brain barrier, a critical step in validating its therapeutic potential for targeting neurodegenerative pathways in ALS.

Polykye™ Platform Reaches Alpha Milestone

The alpha version of our Polykye™ Platform has been completed. This AI-driven system autonomously conducts literature searches to identify high-value disease targets, proposes both novel and existing molecules with desirable properties, and optimizes them for enhanced binding affinity to specific protein targets. By unifying computational target identification, molecular design, and optimization into a single autonomous workflow, Polykye™ streamlines the earliest stages of botanical drug discovery.

Additionally, we have initiated integration with a layer-2 Bitcoin blockchain infrastructure, laying the foundation for future innovation in decentralized bioinformatics.

New CNR-401 Data Presented at ENCALS 2025

At the European Network to Cure ALS (ENCALS) 2025, we presented new preclinical data on CNR-401, our lead botanical extract derived from rare polyphenols. The findings further demonstrate its potential to modulate critical ALS-related pathways, including neuroinflammation, oxidative stress, and neuronal signalling, underscoring our multi-target approach to neurodegenerative disease.

To complement this scientific progress, we also unveiled a new installment of The Healing Project, a series of four visual stories that translate the research into accessible narratives, helping stakeholders visualize the human impact of our work.

Learn More

Showcased at the G7 Canada Brain Economy Summit

We were pleased to participate in the G7 Canada Brain Economy Summit, where we highlighted both our progress in the preclinical pipeline and our approach to science-driven knowledge dissemination through The Healing Project.

The summit provided an important forum to advance conversations on brain health as a critical healthcare and economic priority. We were proud to join fellow Canadian innovators in showcasing the scientific expertise and innovation that are shaping Canada’s growing leadership in this space.

C2MP Update: Accelerating Strategic Growth & Execution

Participation in the Canada-Chicago Mentoring Program (C2MP) continues to provide meaningful insights as we advance both financing and operational initiatives. Mentor guidance is supporting ongoing refinement of our growth strategy, while capital, regulatory, and commercial initiatives are progressing in parallel.